Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 23, 2024 16:53 ET | Source: Service Federal Credit Union

Service Credit Union Pledges to Donate $200,000 to First Responders in Campaign With Charlie McAvoy

Service Credit Union has teamed up with Charlie McAvoy to donate $200,000 toward heart and cancer screenings for first responders.
December 20, 2023 10:28 ET | Source: Research and Markets

Pediatric Perfusion Market Poised for Growth, Expected to Surpass USD 829 Million by 2030

Dublin, Dec. 20, 2023 (GLOBE NEWSWIRE) -- The "Pediatric Perfusion Market Size, Share & Trends Analysis Report By Product (Pediatric Oxygenators, Pediatric Cannulae, Pediatric Blood Pumps), By...
November 30, 2023 03:08 ET | Source: Research and Markets

Global Cardiology IT Workflow Solutions Market Report 2023-2030 - Rise of IT in Healthcare Provides the Foundation for Adoption

Dublin, Nov. 30, 2023 (GLOBE NEWSWIRE) -- The "Cardiology IT Workflow Solutions - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.Global Cardiology IT...
November 21, 2023 16:30 ET | Source: Tenaya Therapeutics, Inc.

Tenaya Therapeutics to Participate at the 35th Annual Piper Sandler Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver...
October 26, 2023 08:30 ET | Source: Tenaya Therapeutics, Inc.

Tenaya Therapeutics Announces FDA Clearance to Begin Clinical Testing of TN-401 Gene Therapy for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy

PKP2 Mutations Are the Leading Cause of ARVC, a Dangerous Condition Linked to Sudden Cardiac Arrest in Young People Estimated to Affect 70,000 People in the US TN-401 Preclinical Studies Demonstrated...
October 25, 2023 06:50 ET | Source: ZyVersa Therapeutics

ZyVersa Therapeutics Announces Research Published in the Peer-Reviewed Journal Diabetes Reinforcing IC 100’s Rationale for Inhibiting ASC to Attenuate Damaging Inflammation Associated with Serious Conditions Such as Obesity-related Heart Disease

Obesity exacerbates scarring of the heart through ASC-driven inflammasome activation in the heart leading to damaging inflammation.
October 17, 2023 06:53 ET | Source: Research and Markets

Cardiovascular Disease Prevalence Sparks Demand in Global Perfusion Disposables Market - Report Analyzes Market Insights Across 39 Countries with Focus on Valvular Health

Dublin, Oct. 17, 2023 (GLOBE NEWSWIRE) -- The "Perfusion Disposables Market Size (Value, Volume, ASP) by Segments, Share, Trend and SWOT Analysis, Regulatory and Reimbursement Landscape, Procedures...
October 09, 2023 08:30 ET | Source: Tenaya Therapeutics, Inc.

Tenaya Therapeutics Presents Encouraging New Clinical and Preclinical Data from HDAC6 Inhibitor Program TN-301 for the Potential Treatment of Heart Failure with Preserved Ejection Fraction at the 2023 HFSA Annual Scientific Meeting

TN-301 Demonstrates Tolerability, Potential for Once Daily Dosing, Target Engagement and Selectivity for HDAC6 in Phase 1 Clinical Trial of Healthy Participants Combination of Tenaya’s HDAC6...
October 05, 2023 08:30 ET | Source: Tenaya Therapeutics, Inc.

Tenaya Therapeutics Doses First Patient in the MyPeak-1™ Phase 1b Clinical Trial of TN-201 for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy

Tenaya Therapeutics announced that the first patient has been dosed with TN-201 gene therapy.
October 02, 2023 17:30 ET | Source: Tenaya Therapeutics, Inc.

Tenaya Therapeutics Publishes Preclinical Data in Circulation Highlighting the Clinical Potential of Cellular Reprogramming for Cardiac Regeneration

Tenaya announced the publication of preclinical research in the October 3, 2023, issue of the American Heart Association’s journal, Circulation.

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right